Tyrosine kinase inhibitors in pediatric malignancies |
| |
Authors: | Skolnik Jeffrey M Adamson Peter C |
| |
Affiliation: | a Division of Clinical Pharmacology and Therapeutics, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA |
| |
Abstract: | Tyrosine kinase inhibitors have been used to treat adult cancers for over a decade. Since the discovery of imatinib mesylate (STI-571, Gleevec; Novartis), tyrosine kinase inhibitors have ushered in a new age of targeted therapy. Although the United States Food and Drug Administration has approved several kinase inhibitors for use in adult cancers, currently only imatinib mesylate is approved for use in children with cancer. This review highlights the mechanisms of tyrosine kinase inhibition, the potential role of tyrosine kinase pathways in the treatment of pediatric cancers, and the current status of pediatric clinical investigation of a spectrum of tyrosine kinase inhibitors for the treatment of childhood cancer. |
| |
Keywords: | Pediatric cancer Tyrosine kinase inhibitors Developmental therapeutics Phase I |
本文献已被 InformaWorld PubMed 等数据库收录! |
|